<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases</h1>
<div class="graphic"><div class="figure"><div class="ttl">Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="15%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Diagnosis [reference]</td> <td class="subtitle1">Age</td> <td class="subtitle1">Procedure and outcome</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td class="centered">[1,2]</td> <td class="centered">4.5 months</td> <td>Orthotopic liver transplantation (OLT) 2 days after hepatocyte transplantation. Explanted liver showed cirrhosis.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Crigler-Najjar syndrome type 1</td> </tr> <tr> <td class="centered">[3]</td> <td class="centered">10 years</td> <td>Total bilirubin reduced by 50%. Bilirubin glucuronide demonstrated in bile up to 3.5 years. Auxiliary liver transplantation (ALTx) after 4 years.</td> </tr> <tr> <td class="centered">[4]</td> <td class="centered">3.5 years</td> <td>Nine infusions were given. Serum bilirubin was reduced by 40% for at least 9 months. Ultimate outcome not reported.</td> </tr> <tr> <td class="centered">[5]</td> <td class="centered">9 years</td> <td>Serum bilirubin was reduced by 32%. OLT after 4.6 months.</td> </tr> <tr> <td class="centered">[6]</td> <td class="centered">8 years</td> <td>Serum bilirubin reduced by 30%. OLT after 11 months.</td> </tr> <tr> <td class="centered">[7]</td> <td class="centered">8 years</td> <td>Hepatocyte transplantation by one percutaneous infusion andÂ eight infusions through an implanted mesenteric Port-a-Cath (PAC) over 5 months. Serum bilirubin was reduced by 40%. OLT after 20 months.</td> </tr> <tr> <td class="centered">[8]</td> <td class="centered">1.5 years</td> <td>Serum bilirubin was reduced by 40%. OLT after 8 months.</td> </tr> <tr> <td class="centered">[8]</td> <td class="centered">3.5 years</td> <td>No clear benefit.</td> </tr> <tr> <td class="centered">[9]</td> <td class="centered">2 years</td> <td>Hepatic progenitor cells were infused through the hepatic artery. Serum bilirubin was reduced by 50%. Ultimate outcome was not reported.</td> </tr> <tr> <td class="centered">[10]</td> <td class="centered">11 years</td> <td>Serum bilirubin was reduced by 20%. On waiting list for OLT.</td> </tr> <tr> <td class="centered">[11]</td> <td class="centered">7 months</td> <td>Serum bilirubin was reduced by 50%, bilirubin levels stable after 1 year. Improvement of psychomotor parameters.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Factor VII deficiency</td> </tr> <tr> <td class="centered">[12]</td> <td class="centered">3 months</td> <td>Requirement of rFVII was reduced by 70%. OLT after 7 months.</td> </tr> <tr> <td class="centered">[12]</td> <td class="centered">35 months</td> <td>Requirement of rFVII was reduced by 70%. OLT after 8 months.</td> </tr> <tr> <td class="centered">[13]</td> <td class="centered">4 months</td> <td>Requirement of rFVII was reduced. Ultimate outcome not reported.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Glycogen storage disease type 1a</td> </tr> <tr> <td class="centered">[11]</td> <td class="centered">6 years</td> <td>Hypoglycemic episodes were reduced. No admission for hypoglycemia at 1-year follow up after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[14]</td> <td class="centered">47 years</td> <td>No hypoglycemia on a normal diet on a 9-month follow up. Long-term outcome not reported.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Glycogen storage disease type 1b</td> </tr> <tr> <td class="centered">[15]</td> <td class="centered">18 years</td> <td>Normal glucose-6-phosphatase activity for 7 months. Ultimate outcome not reported.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Infantile Refsum's disease</td> </tr> <tr> <td class="centered">[16]</td> <td class="centered">4 years</td> <td>Pipecholic acid decreased by 40% and c26:c22 fatty acid ratio by 36% after 18 months. Ultimate outcome not reported.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Phenylketonuria</td> </tr> <tr> <td class="centered">[17]</td> <td class="centered">6 years</td> <td>Patient received hepatocytes from the explanted liver of a patient with glucogen storage disease 1a, and a second transplantation from a deceased donor 7.5 months later. Plasma phenylalanine levels were normalized for 3 months after the second infusion. The therapeutic effect waned after that and patient had to be reinstated on phenylalanine-restricted diet.</td> </tr> <tr> <td class="centered">[18]</td> <td class="centered">27 years</td> <td>Radiation pretreatment followed by hepatocyte transplantation with rejection risk monitoring was associated with lower post-transplant peripheral blood phenylalanine levels.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Primary hyperoxaluria type 1</td> </tr> <tr> <td class="centered">[19]</td> <td class="centered">33 months</td> <td>Reduction of plasma oxalate levels by 25 to 33%. OLT and kidney transplantation after 12 months.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Progressive familial intrahepatic cholestasis type 2</td> </tr> <tr> <td class="centered">[4,8]</td> <td class="centered">32 months</td> <td>Patient had cirrhosis of the liver. No benefit was demonstrated by hepatocyte transplantation. OLT after 5 months.</td> </tr> <tr> <td class="centered">[4,8]</td> <td class="centered">16 months</td> <td>Patient had cirrhosis of the liver. No benefit was demonstrated by hepatocyte transplantation. OLT after 14 months.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Tyrosinemia type 1</td> </tr> <tr> <td class="centered">[11]</td> <td class="centered">45 days</td> <td>Serum bilirubin levels decreased and there was improvement of coagulopathy. OLT after 45 days. Explanted liver had established cirrhosis.</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Urea cycle disorders</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Ornithine transcarbamylase (OTC) deficiency</td> </tr> <tr> <td class="centered">[20]</td> <td class="centered">5 years</td> <td>Blood ammonia level decreased. Biopsy on day 28 showed 0.5% of the OTC activity in normal liver. Patient died of sepsis 42 days after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[21]</td> <td class="centered">10 hours</td> <td>Blood ammonia level decreased. Protein tolerance improved. OLT after 6 months.</td> </tr> <tr> <td class="centered">[22]</td> <td class="centered">Newborn</td> <td>Hepatocytes were infused through the umbilical vein. Blood ammonia level was normal on normal diet. No neurological abnormality developed. OLT after 7 months.</td> </tr> <tr> <td class="centered">[7]</td> <td class="centered">14 months</td> <td>Catheter was malpositioned. Effect of hepatocyte transplantation was not reported. OLT after 6 months.</td> </tr> <tr> <td class="centered">[23]</td> <td class="centered">14 months</td> <td>Blood ammonia was reduced and urea production was increased. There was psychomotor improvement. OLT after 6 months.</td> </tr> <tr> <td class="centered">[24]</td> <td class="centered">1 day</td> <td>Blood ammonia was reduced and urea production was increased. Protein tolerance was improved. ALTx after 7 months.</td> </tr> <tr> <td class="centered">[25]</td> <td class="centered">6 hours</td> <td>Blood ammonia was reduced, urea production was increased, and urinary orotic acid excretion became normal. Patient died 4 months after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[25]</td> <td class="centered">9 days</td> <td>Blood ammonia was reduced, protein tolerance improved, and urinary orotic acid excretion became normal. On waiting list for OLT 6 months after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[26]</td> <td class="centered">5 years</td> <td>Blood ammonia was reduced and glutamine levels were normal. Patient died 45 days after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[22]</td> <td class="centered">1 day</td> <td>Blood ammonia was reduced, urea production increased, and protein tolerance improved. ALTx after 7 months. Patient remained neurologically normal.</td> </tr> <tr> <td class="centered">[11]</td> <td class="centered">12 years</td> <td>Blood ammonia was reduced, urea production increased, and glutamine levels were normal. Patient died of septicemia 30 days after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[27]</td> <td class="centered">11 days</td> <td>Blood ammonia was reduced, and the patient remained neurologically normal 3 months after hepatocyte transplantation.</td> </tr> <tr> <td class="centered">[18]</td> <td class="centered">7 months</td> <td>Radiation pretreatment followed by hepatocyte transplantation was associated with improved protein tolerance post-transplant. However, evaluation of allospecific CD154<sup>+</sup> T-cytotoxic memory cells and their subsets indicated allograft rejection. Patient received liver transplantation at age 11 months.</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Arginosuccinate lyase deficiency</td> </tr> <tr> <td class="centered">[28]</td> <td class="centered">42 months</td> <td>Blood ammonia was reduced and there was psychomotor improvement. OLT after 18 months.</td> </tr> <tr> <td class="centered">[7]</td> <td class="centered">3 years</td> <td>Blood ammonia was reduced. Ultimate outcome was not reported.</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Carbomoyl phosphate synthase I deficiency</td> </tr> <tr> <td class="centered">[29]</td> <td class="centered">2.5 months</td> <td>Blood ammonia was reduced and urea production increased. Patient was on waiting list for OLT 11 months after hepatocyte transplantation.</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Citrulinemia</td> </tr> <tr> <td class="centered">[29]</td> <td class="centered">3 years</td> <td>Blood ammonia was reduced, urea production was increased, and protein tolerance was improved. Ultimate outcome was not reported.</td> </tr> <tr> <td class="centered">[18]</td> <td class="centered">4 months</td> <td>Radiation pretreatment followed by hepatocyte transplantation and immunosuppression resulted in no therapeutic benefit. Evaluation of allospecific CD154<sup>+</sup> T-cytotoxic memory cells and their subsets indicated allograft rejection, and the patient received liver transplantation 3.5 months after hepatocyte transplantation.</td> </tr> </tbody></table></div><div class="graphic_reference">References:
<ol>
<li>Fisher RA, Strom SC. Human hepatocyte transplantation: Worldwide results. Transplantation 2006; 82:441.</li>
<li>Strom SC, Roy-Chowdhury J, Fox IJ. Hepatocyte transplantation for the treatment of human diseases. Semin Liver Dis 1999; 19:39.</li>
<li>Fox IJ, Roy-Chowdhury J, Kaufman SS, et al. Treatment of Crigler-Najjar syndrome type 1 with hepatocyte transplantation. N Eng J Med 1998; 338:1422.</li>
<li>Hughes RS, Mitry RR, Dhawan A. Hepatocyte transplantation for metabolic liver disease: UK experience. J Royal Soc Med 2005; 98:341.</li>
<li>Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005; 14:151.</li>
<li>Allen KJ, Mifsud NA, Williamson R, et al. Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl 2008; 14:688.</li>
<li>Darwish AA, Sokal E, Stephenne X, et al. Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl 2004; 10:1213.</li>
<li>Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29:431.</li>
<li>Khan AA, Parveen N, Mahaboob VS, et al. Treatment of Crigler-Najjar syndrome type 1 by hepatic progenitor cell transplantation: A simple procedure for management of hyperbilirubinemia. Transplant Proc 2008; 40:1148.</li>
<li>Meyburg J, Hoerster F, Schmidt J, et al. Monitoring of intraportal liver cell application in children. Cell Transplant 2010; 19:629.</li>
<li>Ribes-Koninckx C, Ibars EP, Calzado Agrasot MA, et al. Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases. Cell Transplant 2012; 21:2267.</li>
<li>Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited Factor VII deficiency. Transplantation 2004; 78:1812.</li>
<li>Hughes RD, Mitry RR, Dhawan A, et al. Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Cell Transpl 2006; 12:713.</li>
<li>Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment of glycogen storage disease type 1a. Lancet 2002; 359:317.</li>
<li>Lee KW, Lee JH, Shin SW, et al. Hepatocyte transplantation for glycogen storate disease type Ib. Cell Transplant 2007; 16:629.</li>
<li>Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: Technique, safety and metabolic follow-up. Transplantation 2003; 76:735.</li>
<li>Stephenne X, Debray FG, Smets F, et al. Hepatocyte Transplantation Using the Domino Concept in a Child With Tetrabiopterin Nonresponsive Phenylketonuria. Cell Transplant 2012; 21:2765.</li>
<li>Soltys KA, Setoyama K, Tafaleng EN, et al. Host conditioning and rejection monitoring in hepatocyte transplantation in humans. J Hepatol 2017; 66:987.</li>
<li>Beck BB, Habbig S, Dittrich K, et al. Liver cell transplantation in severe infantile oxalosis - a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 2012; 27:2984.</li>
<li>Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc 1997; 29:2101.</li>
<li>Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111:1262.</li>
<li>Mitry RR, Dhawan A, Hughes RD, et al. One liver, three recipients - Segment 4 from split liver procedure as a source of hepatocytes for cell transplantation. Transplantation 2004; 77:1624.</li>
<li>Stephenne X, Najimi M, Smets F, et al. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5:2058.</li>
<li>Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation - a novel treatment for ornithine transcarbamylase deficiency. Am J Transplant 2008; 8:452.</li>
<li>Meyburg J, Das AM, Hoerster F, et al. One liver for four children: First clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009; 87:636.</li>
<li>Bohnen NI, Carron M, Reyes J, et al. Use of Indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal ven infusion. Clin Nucl Med 2000; 25:447.</li>
<li>Ensawa S, Horikwa R, Yamamoto A, et al. Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: a novel source of hepatocytes. Liver Transpl 2014; 20:391.</li>
<li>Stephenne X, Najimi M, Sibille EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for arginosuccinate lyase deficiency. Gastroenterology 2006; 130:1317.</li>
<li>Meyburg K. Alexandrova K, Barthold M, et al. Liver cell transplantation: Basic investigations for safe application in infants and small children. Cell Transplant 2009; 18:777.</li>
</ol></div><div id="graphicVersion">Graphic 67880 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
